Biopharmaceutical oncology company Summit Therapeutics Inc (NASDAQ:SMMT) announced on Monday that it has entered into a clinical trial collaboration with biopharmaceutical company GSK plc (LON:GSK) (NYSE:GSK) to evaluate ivonescimab in combination with GSK's investigational B7-H3 antibody drug conjugate, risvutatug rezetecan, across multiple solid tumour settings, including small cell lung cancer.
Ivonescimab is a novel, investigational PD-1 / VEGF bispecific antibody.
The collaboration with GSK aims to assess the safety profile and potential anti-tumour activity of the combination therapy.
Under the agreement, Summit will supply ivonescimab, while GSK will oversee day-to-day clinical trial operations. Each company will retain rights to its respective product, and the collaboration is structured as non-exclusive.
Clinical trials are expected to begin dosing patients in mid-2026.
Kelun-Biotech reports fourth indication for sac-TMT approved by NMPA in HR+/HER2- breast cancer
Innovent Biologics collaborates with Eli Lilly to develop new oncology and immunology treatments
K36 Therapeutics completes first patient cohort dosing for Phase 1 trial of KTX-2001
Hologic receives FDA approval for Aptima HPV assay as primary screening option
Cizzle Biotechnology secures Canadian patent for lung cancer biomarker test
Biosion reports first patient dosed in Phase 1a/1b trial of BSI-082
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Frontage expands early phase clinical research capabilities across US and China
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
InSysBio agrees new collaborative project with BeOne Medicines